Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmaceutical Medicine

• Publication date

  2017-11-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40290-017-0209-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Early Phase Metabolic Research with Reference to Special Populations

  2019cited by this paper
• Canagliflozin and cardiovascular and renal events in type 2 diabetes

  2018cited by this paper
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

  2017cited by this paper
• Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

  2017cited by this paper
• Novel biomarkers for cardiovascular risk prediction

  2017cited by this paper
• Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus

  2017cited by this paper
• Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.

  2017cited by this paper
• Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness.

  2017cited by this paper
• Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

  2017cited by this paper
• Assessing Cardiovascular Risk and Testing in Type 2 Diabetes

  2017cited by this paper
• Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond

  2017cited by this paper
• Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

  2017cited by this paper
• Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes

  2017cited by this paper
• The Role of Emerging Risk Factors in Cardiovascular Outcomes

  2017cited by this paper
• Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

  2017cited by this paper
• Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes

  2017influential reference
• Evaluation of Endothelial Function by Flow-Mediated Dilation: a Comprehensive Review in Rheumatic Disease

  2017cited by this paper
• Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

  2017cited by this paper
• SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

  2016cited by this paper
• Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.

  2016cited by this paper
• CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• Investigational glucagon-like peptide-1 agonists for the treatment of obesity

  2016cited by this paper
• Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?

  2016cited by this paper
• Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists

  2016cited by this paper
• Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity

  2016cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2016cited by this paper
• The EMPA-REG study: What has it told us? A diabetologist's perspective.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

  2016cited by this paper
• Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.

  2016cited by this paper
• Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

  2016cited by this paper
• Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

  2016cited by this paper
• DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.

  2016cited by this paper
• Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.

  2016cited by this paper
• Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.

  2016cited by this paper
• Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations

  2016cited by this paper
• Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s

  2016cited by this paper
• Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles

  2016cited by this paper
• Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’

  2016cited by this paper
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

  2016cited by this paper
• A clinical perspective of obesity, metabolic syndrome and cardiovascular disease

  2016cited by this paper
• Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

  2016cited by this paper
• Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations

  2016cited by this paper
• Weight management in obesity – past and present

  2016cited by this paper
• Current perspectives on cardiovascular outcome trials in diabetes

  2016cited by this paper
• Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice

  2016influential reference
• Novel Inflammatory Biomarkers in Coronary Artery Disease: Potential Therapeutic Approaches.

  2015cited by this paper
• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

  2015cited by this paper
• Mortality risk among sulfonylureas: a systematic review and network meta-analysis.

  2015cited by this paper
• EMPA-REG OUTCOME: cardiovascular outcome trials in diabetes come of age

  2015cited by this paper
• Pulse wave velocity ratio: the new "gold standard" for measuring arterial stiffness.

  2015cited by this paper
• Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk

  2015influential reference
• Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

  2015cited by this paper
• Current and emerging medications for overweight or obesity in people with comorbidities

  2015cited by this paper
• Insulin Dose and Cardiovascular Mortality in the ACCORD Trial

  2015cited by this paper
• Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.

  2015cited by this paper
• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

  2015cited by this paper
• Global Longitudinal Strain Is a Superior Predictor of All-Cause Mortality in Heart Failure With Reduced Ejection Fraction.

  2015cited by this paper
• Health Benefits of Long-Term Weight-Loss Maintenance.

  2015cited by this paper
• Coronary physiology assessment in the catheterization laboratory.

  2015cited by this paper
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

  2015cited by this paper
• Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium.

  2015cited by this paper
• SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

  2015cited by this paper
• Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate

  2014cited by this paper
• Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.

  2014cited by this paper
• Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk

  2014cited by this paper
• Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

  2014cited by this paper
• Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit

  2014cited by this paper
• Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.

  2014cited by this paper
• The use of dextran and carbon dioxide for optical coherence tomography in the superficial femoral artery.

  2014cited by this paper
• Fractional flow reserve with dobutamine challenge and coronary microvascular endothelial dysfunction in symptomatic myocardial bridging.

  2014cited by this paper
• Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?

  2014cited by this paper
• Pharmacotherapy for obesity: novel agents and paradigms

  2014cited by this paper
• Long-term drug treatment for obesity: a systematic and clinical review.

  2014cited by this paper
• Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials

  2014cited by this paper
• Using positron emission tomography to study human ketone body metabolism: a review.

  2014cited by this paper
• Role of insulin resistance in endothelial dysfunction

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial

  2013cited by this paper
• Pathophysiological roles of FGF signaling in the heart

  2013cited by this paper
• Antiobesity Pharmacotherapy: New Drugs and Emerging Targets

  2013cited by this paper
• Revisiting the links between glycaemia, diabetes and cardiovascular disease

  2013cited by this paper
• Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

  2013cited by this paper
• Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy

  2013cited by this paper
• RAAS inhibition and mortality in hypertension

  2013cited by this paper
• Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations

  2013influential reference
• Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

  2013cited by this paper
• New pharmacological approaches for obesity management

  2013cited by this paper
• Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).

  2013cited by this paper
• Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?

  2013cited by this paper
• Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity

  2013cited by this paper
• Drugs and diabetes: understanding the new breed of cardiovascular safety trials.

  2013cited by this paper
• Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?

  2013cited by this paper
• Therapy of obese patients with cardiovascular disease.

  2013cited by this paper
• Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

  2013cited by this paper
• The Safety and Efficacy of Lorcaserin in the Management of Obesity

  2013cited by this paper

• The risk of cardiovascular complications with current obesity drugs

  2020cites this paper
• Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH

  2019cites this paper